Amgen Inc. Derivative Liability Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31)
Amgen Inc. (AMGN) had Derivative Liability Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) of $0 as of 2011-03-31, per its 10-Q filed 2011-05-10.
Discontinued › Notes › Derivative Instruments and Hedging Activities
us-gaap:DerivativeLiabilityNotDesignatedAsHedgingInstrumentFairValue · last filed 2011-05-10
- 2011-03-31: Derivative Liability Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $0.00.
- 2010-12-31: Derivative Liability Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $0.00.
- 2010-09-30: Derivative Liability Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $0.00.
- 2010-06-30: Derivative Liability Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) $0.00.
| Period end | Derivative Liability Not Designated as Hedging Instrument, Fair Value (Deprecated 2011-01-31) |
|---|---|
| 2011-03-31 | $0.00 10-Q · filed 2011-05-10 |
| 2010-12-31 | $0.00 10-Q · filed 2011-05-10 |
| 2010-09-30 | $0.00 10-Q · filed 2010-11-08 |
| 2010-06-30 | $0.00 10-Q · filed 2010-08-09 |
| 2009-12-31 | $0.00 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |